UK-based liquid biopsy company ANGLE plc (AIM:AGL) (OTCQX:ANPCY) announced on Tuesday that it has secured a contract with Japanese pharmaceutical company Eisai (TYO:4523).
Valued at USD250,000, the agreement entails ANGLE providing circulating tumour cell (CTC) analysis using its Portrait HER2 assay for breast cancer patients in a Phase II study of the HER2 (human epidermal growth factor receptor 2) targeting antibody-drug conjugate (ADC) BB-1701. A successful pilot study could pave the way for extensive follow-up studies.
The Portrait HER2 assay facilitates the quantitative assessment of both HER2 protein expression and HER2/neu gene amplification. This aids in identifying patients suitable for anti-HER2 ADC treatment.
HER2-low breast cancer accounts for 55% of all breast cancer cases. Recognising the market shift towards HER2-low patients, ANGLE has developed a quantitative HER2 assay to ensure accurate patient stratification throughout the treatment journey.
"The use of CTC biomarkers in clinical trials is a rapidly growing field enabling longitudinal monitoring of genomic, transcriptomic and proteomic changes," said ANGLE CEO Andrew Newland. "ANGLE's Portrait HER2 assay provides a way to evaluate HER2 status in patients where a tissue biopsy at the metastatic site either fails or is not feasible."
Analysts predict the global HER2+ breast cancer ADC market will reach USD3.3bn annually by 2030.
Gilead study suggests lenacapavir superior to Truvada
Oxford BioDynamics announces opening of clinical testing facility in UK for prostate screening test
Micron Biomedical names new scientific advisor to CEO
China accepts GSK's Shingrix application for at-risk adults
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Allurion's Gastric Balloon introduced at Somerset NHS Foundation Trust for pre-surgical weight loss
Takeda's HYQVIA gains FDA approval for CIDP maintenance therapy
ANGLE signs USD250,000 contract with Eisai for HER2 assay pilot study
genedrive secures initial overseas orders for Genedrive MT-RNR1 ID kit
Kromek collaborates on next-gen CT detector technology
Gilead Sciences initiates Phase 2 trial in Europe to evaluate lenacapavir for HIV prevention
European Commission grants authorisation to ViiV Healthcare's Apretude for prevention of HIV
Celanese to supply VitalDose drug delivery platform for Population Council's MPT Intravaginal Ring